Literature DB >> 12430173

Rel/NF-kappa B/I kappa B signal transduction in the generation and treatment of human cancer.

Thomas Gilmore1, Maria-Emily Gapuzan, Demetrios Kalaitzidis, Daniel Starczynowski.   

Abstract

The Rel/NF-kappa B family is a group of structurally-related, tightly-regulated transcription factors that control the expression of a multitude of genes involved in key cellular and organismal processes. The Rel/NF-kappa B signal transduction pathway is misregulated in a variety of human cancers, especially ones of lymphoid cell origin, due either to genetic changes (such as chromosomal rearrangements, amplifications, and mutations) or to chronic activation of the pathway by epigenetic mechanisms. Constitutive activation of the Rel/NF-kappa B pathway can contribute to the oncogenic state in several ways, for example, by driving proliferation, by enhancing cell survival, or by promoting angiogenesis or metastasis. In many cases, inhibition of Rel/NF-kappa B activity reverses all or part of the malignant state. Thus, the Rel/NF-kappa B pathway has received much attention as a focal point for clinical intervention.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12430173     DOI: 10.1016/s0304-3835(01)00795-9

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  22 in total

1.  Integrated genomic analysis for prediction of survival for patients with liver cancer using The Cancer Genome Atlas.

Authors:  Yan-Zhou Song; Xu Li; Wei Li; Zhong Wang; Kai Li; Fang-Liang Xie; Feng Zhang
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

Review 2.  When NRF2 talks, who's listening?

Authors:  Nobunao Wakabayashi; Stephen L Slocum; John J Skoko; Soona Shin; Thomas W Kensler
Journal:  Antioxid Redox Signal       Date:  2010-07-09       Impact factor: 8.401

3.  Nuclear IKK activity leads to dysregulated notch-dependent gene expression in colorectal cancer.

Authors:  V Fernández-Majada; C Aguilera; A Villanueva; F Vilardell; A Robert-Moreno; A Aytés; F X Real; G Capella; M W Mayo; L Espinosa; A Bigas
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-26       Impact factor: 11.205

4.  Effect of mutated IkappaBalpha transfection on multidrug resistance in hilar cholangiocarcinoma cell lines.

Authors:  Ru-Fu Chen; Zhi-Hua Li; Xian-He Kong; Ji-Sheng Chen
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

5.  Okadaic acid induces tyrosine phosphorylation of IkappaBalpha that mediated by PKR pathway in human osteoblastic MG63 cells.

Authors:  Hiroyuki Morimoto; Akiko Ozaki; Hirohiko Okamura; Kaya Yoshida; Seiichiro Kitamura; Tatsuji Haneji
Journal:  Mol Cell Biochem       Date:  2005-08       Impact factor: 3.396

Review 6.  Chemokines: novel targets for breast cancer metastasis.

Authors:  Simi Ali; Gwendal Lazennec
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

7.  Stimulation of c-Rel transcriptional activity by PKA catalytic subunit beta.

Authors:  Shih-Hung Yu; Wei-Chung Chiang; Hsiu-Ming Shih; Kou-Juey Wu
Journal:  J Mol Med (Berl)       Date:  2004-06-09       Impact factor: 4.599

8.  Mechanisms underlying differential expression of interleukin-8 in breast cancer cells.

Authors:  Ariane Freund; Valérie Jolivel; Sébastien Durand; Nathalie Kersual; Dany Chalbos; Carine Chavey; Françoise Vignon; Gwendal Lazennec
Journal:  Oncogene       Date:  2004-08-12       Impact factor: 9.867

9.  Bioactive 5,6-dihydro-alpha-pyrone derivatives from Hyptis brevipes.

Authors:  Ye Deng; Marcy J Balunas; Jeong-Ah Kim; Daniel D Lantvit; Young-Won Chin; Heebyung Chai; Sugeng Sugiarso; Leonardus B S Kardono; Harry H S Fong; John M Pezzuto; Steven M Swanson; Esperanza J Carcache de Blanco; A Douglas Kinghorn
Journal:  J Nat Prod       Date:  2009-06       Impact factor: 4.050

10.  Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.

Authors:  Minsu Kwon; Hyejin Jang; Eun Hye Kim; Jong-Lyel Roh
Journal:  Cell Cycle       Date:  2016-09-29       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.